Stock Track | BeiGene Stock Plummets 5.83% on Tuesday, Recovery Expected in 2025

Stock Track12-10

BeiGene, a Chinese biopharmaceutical company, saw its stock (BGNE) plummet by 5.83% on Tuesday during the intraday trading session.

Despite the plunge, analysts at Deutsche Bank believe that the recovery momentum seen in China's healthcare companies, including BeiGene, since mid-August is expected to continue in 2025. This recovery is anticipated to be driven by the following factors:

The Chinese government's supportive policy on innovative drugs and pricing
An expected improvement in biotech funding environment

According to Cyrus Ng, an analyst at Deutsche Bank, China's healthcare stocks have lagged behind the Hang Seng Index in 2024 amid geopolitical tensions and a difficult biotech funding environment. However, with improved sentiment and the government's supportive measures, China's biotech funding is expected to start recovering gradually in 2025.

Disclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.

Comments

We need your insight to fill this gap

Leave a comment

{"i18n":{"language":"en_US"},"isChannel":false,"data":{"share":"https://ttm.financial/m/news/1183254431?lang=en_US&edition=fundamental","thumbnail":"","is_english":true,"pubTime":"2024-12-10 22:34","share_image_url":"https://static.laohu8.com/e9f99090a1c2ed51c021029395664489","id":"1183254431","market":"hk","top_or_hot":-1,"title":"Stock Track | BeiGene Stock Plummets 5.83% on Tuesday, Recovery Expected in 2025","media":"Stock Track","content":"<p>BeiGene, a Chinese biopharmaceutical company, saw its stock (BGNE) plummet by 5.83% on Tuesday during the intraday trading session.</p>\n\n<p>Despite the plunge, analysts at Deutsche Bank believe that the recovery momentum seen in China's healthcare companies, including BeiGene, since mid-August is expected to continue in 2025. This recovery is anticipated to be driven by the following factors:</p>\n\n<ul>\n<li>The Chinese government's supportive policy on innovative drugs and pricing</li>\n<li>An expected improvement in biotech funding environment</li>\n</ul>\n\n<p>According to Cyrus Ng, an analyst at Deutsche Bank, China's healthcare stocks have lagged behind the Hang Seng Index in 2024 amid geopolitical tensions and a difficult biotech funding environment. However, with improved sentiment and the government's supportive measures, China's biotech funding is expected to start recovering gradually in 2025.</p>","source":"ai_movement_en","html":"<!DOCTYPE html>\n<html>\n<head>\n<meta http-equiv=\"Content-Type\" content=\"text/html; charset=utf-8\" />\n<meta name=\"viewport\" content=\"width=device-width,initial-scale=1.0,minimum-scale=1.0,maximum-scale=1.0,user-scalable=no\"/>\n<meta name=\"format-detection\" content=\"telephone=no,email=no,address=no\" />\n<title>Stock Track | BeiGene Stock Plummets 5.83% on Tuesday, Recovery Expected in 2025</title>\n<style type=\"text/css\">\na,abbr,acronym,address,applet,article,aside,audio,b,big,blockquote,body,canvas,caption,center,cite,code,dd,del,details,dfn,div,dl,dt,\nem,embed,fieldset,figcaption,figure,footer,form,h1,h2,h3,h4,h5,h6,header,hgroup,html,i,iframe,img,ins,kbd,label,legend,li,mark,menu,nav,\nobject,ol,output,p,pre,q,ruby,s,samp,section,small,span,strike,strong,sub,summary,sup,table,tbody,td,tfoot,th,thead,time,tr,tt,u,ul,var,video{ font:inherit;margin:0;padding:0;vertical-align:baseline;border:0 }\nbody{ font-size:16px; line-height:1.5; color:#999; background:transparent; }\n.wrapper{ overflow:hidden;word-break:break-all;padding:10px; }\nh1,h2{ font-weight:normal; line-height:1.35; margin-bottom:.6em; }\nh3,h4,h5,h6{ line-height:1.35; margin-bottom:1em; }\nh1{ font-size:24px; }\nh2{ font-size:20px; }\nh3{ font-size:18px; }\nh4{ font-size:16px; }\nh5{ font-size:14px; }\nh6{ font-size:12px; }\np,ul,ol,blockquote,dl,table{ margin:1.2em 0; }\nul,ol{ margin-left:2em; }\nul{ list-style:disc; }\nol{ list-style:decimal; }\nli,li p{ margin:10px 0;}\nimg{ max-width:100%;display:block;margin:0 auto 1em; }\nblockquote{ color:#B5B2B1; border-left:3px solid #aaa; padding:1em; }\nstrong,b{font-weight:bold;}\nem,i{font-style:italic;}\ntable{ width:100%;border-collapse:collapse;border-spacing:1px;margin:1em 0;font-size:.9em; }\nth,td{ padding:5px;text-align:left;border:1px solid #aaa; }\nth{ font-weight:bold;background:#5d5d5d; }\n.symbol-link{font-weight:bold;}\n/* header{ border-bottom:1px solid #494756; } */\n.title{ margin:0 0 8px;line-height:1.3;color:#ddd; }\n.meta {color:#5e5c6d;font-size:13px;margin:0 0 .5em; }\na{text-decoration:none; color:#2a4b87;}\n.meta .head { display: inline-block; overflow: hidden}\n.head .h-thumb { width: 30px; height: 30px; margin: 0; padding: 0; border-radius: 50%; float: left;}\n.head .h-content { margin: 0; padding: 0 0 0 9px; float: left;}\n.head .h-name {font-size: 13px; color: #eee; margin: 0;}\n.head .h-time {font-size: 11px; color: #7E829C; margin: 0;line-height: 11px;}\n.small {font-size: 12.5px; display: inline-block; transform: scale(0.9); -webkit-transform: scale(0.9); transform-origin: left; -webkit-transform-origin: left;}\n.smaller {font-size: 12.5px; display: inline-block; transform: scale(0.8); -webkit-transform: scale(0.8); transform-origin: left; -webkit-transform-origin: left;}\n.bt-text {font-size: 12px;margin: 1.5em 0 0 0}\n.bt-text p {margin: 0}\n</style>\n</head>\n<body>\n<div class=\"wrapper\">\n<header>\n<h2 class=\"title\">\nStock Track | BeiGene Stock Plummets 5.83% on Tuesday, Recovery Expected in 2025\n</h2>\n\n<h4 class=\"meta\">\n\n2024-12-10 22:34 北京时间&nbsp;&nbsp;&nbsp;<strong>Stock Track</strong>\n\n</h4>\n\n</header>\n<article>\n<div>\n<p>BeiGene, a Chinese biopharmaceutical company, saw its stock (BGNE) plummet by 5.83% on Tuesday during the intraday trading session.\nDespite the plunge, analysts at Deutsche Bank believe that the ...</p>\n\n<a href=\"\">Source Link</a>\n\n</div>\n\n\n</article>\n</div>\n</body>\n</html>\n","isBrief":false,"type":0,"news_type":1,"symbol":"BGNE","symbol_name":"百济神州","start_time":0,"source_url":"","article_id":"1183254431","we_media_id":"1086803395","thumbnails":[],"rights":null,"url":"https://stock-news.laohu8.com/highlight/detail?id=1183254431","pubTimestamp":1733841298,"columns":[],"sourceInfo":{"source_id":"ai_movement_en","name":"Stock Track"},"weMediaInfo":{"media_name":"Stock Track","introduction":"Track stock‘s movements and relevant news","home_visible":1,"id":"1086803395","head_image":"https://static.tigerbbs.com/a81accab1e7ee4144dc051f71903a390"},"summary":"BeiGene, a Chinese biopharmaceutical company, saw its stock  plummet by 5.83% on Tuesday during the intraday trading session.Despite the plunge, analysts at Deutsche Bank believe that the recovery momentum seen in China's healthcare companies, including BeiGene, since mid-August is expected to continue in 2025. This recovery is anticipated to be driven by the following factors:. The Chinese government's supportive policy on innovative drugs and pricing. According to Cyrus Ng, an analyst at Deuts","collect":0,"end_time":0,"defaultTopTitle":"","property":[],"viewcount":null,"language":"en","relate_stocks":{"BGNE":"百济神州"},"translate_title":"股票赛道百济神州股价周二暴跌5.83%预计2025年复苏","themeId":"","isJumpTheme":false,"ttsUrl":null,"symbols_score_info":{"BGNE":1},"content_text":"BeiGene, a Chinese biopharmaceutical company, saw its stock (BGNE) plummet by 5.83% on Tuesday during the intraday trading session.\nDespite the plunge, analysts at Deutsche Bank believe that the recovery momentum seen in China's healthcare companies, including BeiGene, since mid-August is expected to continue in 2025. This recovery is anticipated to be driven by the following factors:\n\nThe Chinese government's supportive policy on innovative drugs and pricing\nAn expected improvement in biotech funding environment\n\nAccording to Cyrus Ng, an analyst at Deutsche Bank, China's healthcare stocks have lagged behind the Hang Seng Index in 2024 amid geopolitical tensions and a difficult biotech funding environment. However, with improved sentiment and the government's supportive measures, China's biotech funding is expected to start recovering gradually in 2025.","kind":"news","is_publish_news":true,"is_publish_highlight":false,"is_publish_live":false,"is_publish_wemedia":null,"editions":null,"column":"","sentiment":"-1","news_tag":"movement","news_rank":0,"symbols":[],"gpt_button":1},"commentList":[],"isCommentEnd":true,"newsSizeData":{"likeSize":0,"commentSize":0,"repostSize":0,"favoriteSize":0,"likeStatus":false,"favoriteStatus":false},"APP":{"userAgent":"Mozilla/5.0 AppleWebKit/537.36 (KHTML, like Gecko; compatible; ClaudeBot/1.0; +claudebot@anthropic.com)","isDev":false,"isTTM":true,"deviceId":"web-server-community-laohu8-v3","version":"4.29.3","shortVersion":"4.29.3","platform":"web","vendor":"web","appName":"ttm","isIOS":false,"isAndroid":false,"isTiger":false,"isTHS":false,"isWeiXin":false,"isWeiXinMini":false,"isWeiBo":false,"isQQ":false,"isBaiduSwan":false,"isBaiduBox":false,"isDingTalk":false,"isToutiao":false,"isOnePlus":false,"isHuaWei":false,"isXiaomi":false,"isXiaomiWebView":false,"isOppo":false,"isVivo":false,"isSamsung":false,"isMobile":false},"href":"/m/news/1183254431"}